Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Since the first cases of COVID-19 were documented in Wuhan, China in 2019, the world has
witnessed a devastating global pandemic, with more than 238 million cases, nearly 5 million …

The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread
rapidly to become globally dominant and has split into a number of sublineages. BA. 1 …

Infectious viral load (VL) expelled as droplets and aerosols by infected individuals partly
determines transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B. 1.1.
529 was announced, containing far more mutations in Spike (S) than previously reported …

Summary Background Several SARS-CoV-2 variants of concern have been identified that
partly escape serum neutralisation elicited by current vaccines. Studies have also shown …

The past several months have witnessed the emergence of SARS-CoV-2 variants with novel
spike protein mutations that are influencing the epidemiological and clinical aspects of the …

With the constantly mutating of SARS-CoV-2 and the emergence of Variants of Concern
(VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 …

Background Vaccines are critical cost-effective tools to control the coronavirus disease 2019
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …

There is an urgent need for an effective, oral, direct-acting therapeutic to block transmission
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression …